Use of Tamoxifen in Systemic Mastocytosis

Mayo Clinic

Status: Completed

Conditions: Systemic Mastocytosis

Study type: Observational

Funder types: Other

Identifiers

NCT01334996

2506-04

Details and patient eligibility

About

In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine will be excluded until these medications have been stopped.

Full description

Not desired

Enrollment: 1 patient

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Systemic Mastocytosis

Exclusion criteria

• Current treatment with Imatinib mesylate, cladribine or interferon alpha.